ArticleFrontiers in cardiovascular medicine2026
Clinical correlates of lipoprotein (a) and apolipoprotein B levels in patients with dyslipidemia and cardiovascular disease.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerotic cardiovascular disease remains a major cause of morbidity and mortality worldwide, with residual cardiovascular risk persisting despite optimized lipid-lowering therapy. Lipoprotein(a) [Lp(a)] and apolipoprotein B (ApoB) have emerged as independent, causal biomarkers of cardiovascular risk, reflecting atherogenic particle burden beyond conventional lipid measures. This study aimed to evaluate the clinical, metabolic, and biochemical correlates of Lp(a) and ApoB levels in patients with dyslipidemia and cardiovascular disease. Methods: A cross-sectional observational analysis was performed in 153 adults evaluated for cardiometabolic risk. Anthropometric, biochemical, and inflammatory parameters were assessed. Correlation analyses were conducted to identify associations between lipoproteins and metabolic variables. Decision tree regression was used to explore distribution patterns of Lp(a) and ApoB variability. Results: The study population exhibited a mean age of 57.9 ± 12.3 years, with a predominance of dyslipidemia (79.1%) and established cardiovascular disease (75.2%). The mean Lp(a) concentration was 30.14 ± 31.50 mg/dL, while ApoB averaged 119.87 ± 36.01 mg/dL. ApoB correlated significantly with total cholesterol ( Conclusions: Both hepatic and renal function markers significantly modulate Lp(a) levels, while ApoB remains a robust indicator of atherogenic particle load. Integrating Lp(a) and ApoB assessment into cardiovascular risk profiling may improve identification of residual risk and guide personalized therapeutic strategies in dyslipidemic populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.